# Experiencia con la mesa prona Affirm Tomobiopsia y Brevera

Dr. Alejandro Tejerina Bernal

Centro de Patología de la Mama. Madrid.







## **DISCLOSURE**

• No potential conflicts of interest to disclose.





# **OBJECTIVES**

- Describe how the addition of 3D mammography to current practice can introduce new challenges that can be solved with Tomosynthesis biopsy.
- Explain the main clinical benefits of 3D image-guided biopsy with Tomosynthesis.
- •Analize the implementation of Brevera® breast biopsy system with real-time imaging verification (CorLumina®) in our center. Initial results.





## **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusion.





## **SUMMARY**


- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.





## Image guided Incisional Breast Biopsy


Procedure to obtain a representative histological sample of a suspicious lesion








## The image finding will determine the type of biopsy









## Stereotactic Breast Biopsy













## Stereotactic Fundamentals















## **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.





## 3D MAMMOGRAPHY

- ACTUAL MAMMOGRAPHY.
- Reduce false positive screening recalls.
- Increase in Cancer detection rate: invasive and DCIS.





Radiology. 2013 Apr;267(1):47-56. doi: 10.1148/radiol.12121373. Epub 2013 Jan 7.

## Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program.

Skaane P1, Bandos Al, Gullien R, Eben EB, Ekseth U, Haakenaasen U, Izadi M, Jebsen IN, Jahr G, Krager M, Niklason LT, Hofvind S, Gur D.

#### Radiology, 2013 Jan 7

For complete findings, please click here http://radiology.rsna.org/content/early/2013/01/01/radiol.12121373.full

#### **OBJECTIVE**

This study was performed to assess cancer detection rates and false-positive rates before arbitration, positive predictive values for women recalled after arbitration, and the type of cancers detected with use of digital mammography alone and digital mammography combined with tomosynthesis in a large prospective screening trial

#### **MATERIALS AND METHODS**


12631 women who gave written consent from November 22, 2010 to December 31, 2011 participated in this prospective screening study. An interim analysis of results from these examinations was performed and the results were independently read and interpreted by four different radiologists. These examinations were interpreted by using digital mammography alone and digital mammography plus tomosynthesis

#### **FINDINGS**

	Digital Mammography alone: number/1000 women screened	Digital Mammography plus Tomosynthesis: number/1000 women screened	Relative Change: adjusted for reader
False-positive rate before arbitration	61.1	53.1	<b>↓</b> 15%
Cancer Detection Rate (invasive and in-situ cancers)	6.1	8.0	<b>↑</b> 27%
Cancer Detection Rate (invasive cancers)	4.4 (56 detected)	6.4 (81 detected)	↑40% (25 additional)

#### CONCLUSION

The authors concluded that the addition of tomosynthesis to digital mammography in the screening population resulted in a significant increase in cancer detection rate, particularly for invasive cancers, and a simultaneous significant decrease in false-positive rate. The increase was observed across all breast densities.



#### **Relative Change:**

adjusted for reader

**↓**15%

**1**27%


↑40% (25 additional)









Everything is sharper and clearer in 3D.





















Centro de Patología de la Mama

# 3D BIOPSY JUSTIFICATION





CONVENTIONAL STEREOTACTIC PRONE TABLE



## **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.





# BREAST TOMOSYNTHESIS GUIDED BIOPSY







2013 AFFIRM Vertical 2016 AFFIRM Prone





### AFFIRM 3D BIOPSY





#### **3D UPRIGHT**

- Image quality
- Wider biopsy window
- Access some posterior lesions
- Tomo biopsy +++++
- Cost

#### **3D PRONE**

- Dedicated room +++
- Better patient tolerance
- Wider biopsy window
- Image quality
- Tomo biopsy +++++





## **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.













## PRONE TABLE CENTRO DE PATOLOGÍA DE LA MAMA













# Affirm PRONE



## CLINICAL ADVANTAGES

- Ergonomic improvements.
- Software improvements.
- •Image capability: 3D and selenium detector.
- •Problem solving in complex biopsies.
- •Excellent patient experience.





## Complex biopsies

• Thin Breast Compression (Less than 2.5 cm).

C-Arm

- Subtle microcalcifications.
- Low-Contrast lesions: Distortions (3D).






## Lateral Access C-Arm










































































DCIS



# Challenging lesions





































Low Grade DCIS

























































Atypical Ductal Hyperplasia








ECR 2017









FINDING	Mean Size (mm)	% Malignancy	% High Risk	% Benign Changes
Calcifications High-Contrast	14,83	24,60 %	22,99 %	51,87 %
Mass Low-Contrast	11,44	39,53 %	13,93 %	46,51 %
Focal Asimmetry	10,14	17,24 %	13,79 %	68,97%
Distortion  Low- Contrast	12,81	25,81 %	58,06 %	16,13%





ECR 2017

		Affirm Prone (Tejerina Foundation)	Affirm vertical (Schrading) (1)	Conventional PS (Schrading) (1)
		n = 100	n = 51	n = 165
Total time	Mean	$21.32 \pm 6.57$	12.9 3± .7	29.11± 0.1
	Median	20 (7-42)	13 (8-32)	28 (12-65)
Targeting time	Mean	1.65± 2.11	4.1± 1.8	15.0± 9.3
	Median	1 (1-14)	4 (2-12)	12 (2-34)
Sampling time	Mean	4.61 ± 3.40	$8.3 \pm 2.6$	$10.3 \pm 4.5$
	Median	4 (1-17)	8 (4-21)	9 (5-31)



(1) Schrading S, Distemaier M, Dirrichs T, et al. Digital Breast Tomosynthesis-guided Vaccum-assisted Breast Biopsy: Initial Experiences and Comparison with Prone Stereotactic Vaccum-assisted Biopsy. Radiology 2015;274 (3)



		Affirm Prone (Tejerina Foundation) n = 100	Affirm vertical (Schrading) (1) n = 51	Conventional PS (Schrading) (1) n = 165
No. of images	Median	6 (3-14)	5 (4-8)	8 (5-13)





Overall Patient Experience	Affirm Prone (Tejerina Foundation) n = 100	% No.of patients
1	Excellent	84%
2	Very Good	12%
3	Good	3%
4	Fair	0%
5	Poor	0%





#### **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.





## Brevera® Breast Biopsy System with CorLumina® Imaging Technology





Vaccum assisted breast biopsy system with real-time imaging (CorLumina®) for instant verification and automated post-biopsy specimen handling.





Technologist Display

Driver-Biopsy Device

Main Components




HOLOGIC

Vacuum line assembly and suction canister

Imaging Display


Tissue filter drawer



Centro de Patología de la

Footswitch





Steps for assembly













HOLOGIC'




# Steps for assembly









# Steps for assembly














## The Test Mode



## Tissue Filter Components

Tissue filter



FUNDACIÓN TEJERINA

Tissue filter chamber (12 chambers) Tissue filter chamber indicator (12 letter designation) Centro de Patología

de la











## How does it work?











### POTENTIAL CLINICAL ADVANTAGES

- Fast procedures
- Optimized technologist workflow
- Fewer steps
- Separates samples for pathology
- Improved sample identification
- Patient satisfaction





#### **BREVERA BREAST BIOSY SYSTEM**






SAME PROCEDURE




## **USUAL WORKFLOW**






















## **USUAL WORKFLOW**





















## **BREVERA WORKFLOW**







































## MULTICENTER STUDY

- CE MARKET
- July 2016. Animal Study. "GLP Acute Evaluation of the Brevera Vaccum-Assisted Breast Biopsy System in the Porcine Model".
- "A Retrospective/Prospective Study to Evaluate the Performance and operation of the Brevera Breast Biopsy System"
- Retrospective/Prospective. Multicenter (Up to 10 sites). Controlled Data Collection Study.





## **MULTICENTER STUDY**










# **CASE**















































# **CASE**


















Centro de Patología de la Mama







Sclerosin adenosis



#### **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.





## Brevera®. Our initial results





### MULTICENTER STUDY

- First 60 cases.
- 58 patients.
- 56 simple and 2 double biopsies.
- Mean age: 57 years.






BREAST DENSITY	
ACR A	3,23%
ACR B	53,23%
ACR C	37,10%
ACR D	6,45%

IMAGE FINDING	
Microcalcifications	70,97 %
Distortion	29,03%
Mass	0%

MEAN SIZE	N 60
mm.	10.05












### BIOPSY UNDERESTIMATION


- Number of cores
- Size (gauges)
- Correct targeting
- Calcifications in our sample
- Radiopathologic correlation
- Type of lesión
- Enviroment of the lesion





## BIOPSY UNDERESTIMATION







BREVERA ADDING VALUE?



NUMBER OF SAMPLES	N 60
Mean	9,23

	NUMBER OF SAMPLES WITH CALCIFICATIONS
Mean	4





NEEDLE CAMERA	
Standard (20 mm)	90 % (54)
Petite (12 mm)	10% (6)

WEIGHT	
Average per lesion	2,30 g
Average per sample	0,24 g










3 different cases and sample variability related to individual bleeding











3 min.



1,42 min.

SETUP TIME

FUNDACIÓN TEJERINA



12 SAMPLES TIME




1 min.



52 seg.







- 2. FAIR
- GOOD
- 4. VERY GOOD
- 5. EXCELLENT





#### **SUMMARY**

- Introduction.
- 3D Biopsy. Justification.
- 3D Biopsy. Upright and Prone.
- 3D Prone Biopsy. Clinical Advantages.
- Brevera® Breast Biopsy System with CorLumina® Imaging Technology.
- Brevera®. Our results.
- Conclusions.





#### **CONCLUSIONS**

- 3D biopsy is a necessary solution in the day to day diagnostic work.
- Affirm prone dedicated table has shown significant improvements in image quality that facilitates complex biopsies.
- Brevera is a tool that offers confidence to physicians in breast biopsy procedures, specially in the cases of microcalcifications.
- More studies need to be done to demonstrate that biopsies with less amount of tissue can be done without risk of underestimation.
- The 3D biopsy combined with the implementation of a Brevera system make the biopsy procedure more accurate and safe.











Universidad Complutense de Madrid Cátedra Extraordinaria de Patología de la Mama Fundación Tejerina

